← All trials
NCT01550055
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2009
- Primary completion
- Dec 1, 2015
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 512
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shanghai Zhangjiang Biotechnology Limited CompanyLead sponsor
- Central South UniversityOverall official - principal investigator
- NanKai UniversityOverall official - principal investigator
- Shandong Provincal Cancer HospitalOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Tsinghua UniversityOverall official - principal investigator
- Chinese Medical UniversityOverall official - principal investigator
- Anhui Medical UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Gansu Provincial HospitalOverall official - principal investigator
- Guangxi Medical UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Xiamen UniversityOverall official - principal investigator
- Nantong UniversityOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Shanghai Biomabs Pharmaceuticals Co LtdCollaborator
- People's Liberation Army of ChinaOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesStudy chair
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.